Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISTH0036 in Primary Open-Angle Glaucoma Undergoing Trabeculectomy
NCT02406833Phase 1Completed
- Sponsor
- Isarna Therapeutics
- Start
- Apr 2015
- Primary completion
- Aug 2016
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tgf-β2 antisense oligonucleotide in primary open-angle glaucoma (POAG), sponsored by Isarna Therapeutics. Primary endpoint: Safety and tolerability as assessed by clinical monitoring and reporting of adverse events (AE) and serious adverse events (SAE) at 1 year. Started Apr 2015; status: completed.
02
Drugs
tgf-β2 antisense oligonucleotide
03
Conditions
primary open-angle glaucoma (POAG)
Beyond the preview
Go deeper on NCT02406833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02406833.